Dermatological conditions are among the most common diseases encountered by healthcare professionals and their impact can severely affect a patient’s quality of life. The dermatology brand Hydromol® was acquired in 2006 and is one of the key brands treating atopic eczema in the UK. Atopic eczema disease accounting for 30% of all dermatoloical consultations in general practice. Innovation within dermatology is also highly important and in June 2013 we launched MolluDab®, a treatment for the previously poorly managed condition Molluscum Contagiosum.
- Medical device